Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback